New Journal Website is available at: http://www.journalonweb.com/rcm

Published by: Kowsar

Clinical Implications of Recent Trials on Anticoagulation in Patients with Atrial Fibrillation

Arash Arya 1 , * , Simon Kircher 1 , Andreas Müssigbrodt 1 , Charlotte Eitel 1 , Philipp Sommer 1 and Gerhard Hindricks 1
Authors Information
1 Department of Electrophysiology, Heart Centre University of Leipzig, Leipzig, Germany
Article information
  • Research in Cardiovascular Medicine: November 1, 2012, 1 (1); 3-9
  • Published Online: November 1, 2012
  • Article Type: Review Article
  • Received: May 10, 2012
  • Revised: May 20, 2012
  • Accepted: May 27, 2012
  • DOI: 10.5812/cardiovascmed.6541

To Cite: Arya A, Kircher S, Müssigbrodt A, Eitel C, Sommer P, et al. Clinical Implications of Recent Trials on Anticoagulation in Patients with Atrial Fibrillation, Res Cardiovasc Med. 2012 ;1(1):3-9. doi: 10.5812/cardiovascmed.6541.

Copyright: Copyright © 0, Research in Cardiovascular Medicine. .
1. Introduction
2. Role of Risk Stratification Scores in the Stroke Prevention
3. Role of Risk Stratification Scores in the Bleeding Prevention
4. Role of New Oral Anticoagulants in the Stroke Prevention
5. Role of Catheter Ablation in the Stroke Prevention
6. Cost-effectiveness of New Oral Anticoagulants
7. Conclusion
Footnotes
References
  • 1. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31(19): 2369-429[DOI][PubMed]
  • 2. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006; 114(7)-354[DOI][PubMed]
  • 3. Wann LS, Curtis AB, Ellenbogen KA, Estes NA, 3rd, Ezekowitz MD, Jackman WM, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011; 123(10): 1144-50[DOI][PubMed]
  • 4. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139-51[DOI][PubMed]
  • 5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883-91[DOI][PubMed]
  • 6. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981-92[DOI][PubMed]
  • 7. Skanes AC, Healey JS, Cairns JA, Dorian P, Gillis AM, McMurtry MS, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012; 28(2): 125-36[DOI][PubMed]
  • 8. Lansberg MG, O'Donnell MJ, Khatri P, Lang ES, Nguyen-Huynh MN, Schwartz NE, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl)-36S[DOI][PubMed]
  • 9. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm. 2012; 9(4): 632-96 e21[DOI][PubMed]
  • 10. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004; 110(9): 1042-6[DOI][PubMed]
  • 11. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22(8): 983-8[PubMed]
  • 12. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137(2): 263-72[DOI][PubMed]
  • 13. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011; 342[DOI][PubMed]
  • 14. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwide cohort study. Thromb Haemost. 2012; 107(6)[DOI][PubMed]
  • 15. Pieri A, Lopes TO, Gabbai AA. Stratification with CHA2DS2-VASc score is better than CHADS2 score in reducing ischemic stroke risk in patients with atrial fibrillation. Int J Stroke. 2011; 6(5): 466[DOI][PubMed]
  • 16. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007; 370(9586): 493-503[DOI][PubMed]
  • 17. Alberts MJ, Bhatt DL, Smith SC, Rother J, Goto S, Hirsch AT, et al. Risk factors and outcomes for patients with vascular disease and serious bleeding events. Heart. 2011; 97(18): 1507-12[DOI][PubMed]
  • 18. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011; 123(2): 131-6[DOI][PubMed]
  • 19. Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2012; 59(13): 1168-74[DOI][PubMed]
  • 20. Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2012; 23(3): 264-8[DOI][PubMed]
  • 21. Saad EB, d'Avila A, Costa IP, Aryana A, Slater C, Costa RE, et al. Very low risk of thromboembolic events in patients undergoing successful catheter ablation of atrial fibrillation with a CHADS2 score </=3: a long-term outcome study. Circ Arrhythm Electrophysiol. 2011; 4(5): 615-21[DOI][PubMed]
  • 22. Welles CC, Whooley MA, Na B, Ganz P, Schiller NB, Turakhia MP. The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: data from the Heart and Soul Study. Am Heart J. 2011; 162(3): 555-61[DOI][PubMed]
  • 23. Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace. 2012; 14(1): 8-27[DOI][PubMed]
  • 24. Kamel H, Johnston SC, Easton JD, Kim AS. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke. 2012; 43(3): 881-3[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader